+ News | etiraRx News | etiraRx News


April 18, 2023

Positive preclinical data presented at AACR 2023

Dallas, Texas April 17, 2023 Etira is pleased to announce that multiple abstracts related to their licensed products showed encouraging preclinical activity in metastatic breast cancer and ovarian cancer. The...

April 17, 2023

Etira founder Dr. Ratna Vadlamudi honored with the prestigious 2023 Distinguished Research Scholar Award

April 18, 2023 Dallas, Texas We are excited to congratulate one of our founders, Dr. Ratna Vadlamudi, Professor and Vice Chair for Research, Division of Reproductive Research, Department of Obstetrics...

December 9, 2022

Preclinical data on TNBC presented at SABCS 2022

Dallas, Texas Dec 9, 2022: Etira is pleased to report the abstract related to ERX-41 validating its activity in Triple negative breast cancer was presented at the San Antonio Breast...

October 10, 2022

Oncology Times Highlights ERX-41

etiraRx's lead drug candidate, ERX-41 has been highlighted in the most recent edition of Oncology Times. In an article entitled "Molecule Targets Vulnerability in Triple-Negative Breast Cancer," Dibash Kumar Das,...

July 1, 2022

Scientific News Media Features the Discovery of ERX-41, the Novel Mechanism of Action and Novel Molecular Target

Following the publication of the article “Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress” in Nature Cancer, from...

June 3, 2022

EtiraRx’s Licensed ERX-41 Identified as a Potential New Oral Therapy for Multiple Cancers, Company Prepares for Clinical Trials

DALLAS, June 2, 2022 /PRNewswire/ -- A scientific team, led by the scientific founders of EtiraRx, has identified a small molecule, ERX-41, as a novel oral therapeutic agent that may have utility...